Grønningen 25
DK-1270 Copenhagen K
Tel. +45 33 63 09 00
Fax +45 33 63 09 29

7 September 2007

Innovision obtains important approval in the USA

Innovision, a subsidiary of M. Goldschmidt Capital, has obtained an important approval from the US authorities, as the US Food & Drug Administration has approved Innovision’s Innocor® equipment to be used for metabolic exercise testing, during which a patient’s cardiovascular function is examined by means of advanced analysis of the patient’s exhalation.

“The approval is a very important step on the way towards a successful entry into the US market”, says Søren Bjørn Hansen, CEO of M. Goldschmidt Capital and member of the board of Innovision.

Read more about M. Goldschmidt Capital’s involvement in Innovision.

Other news

Back to overview